AUM Biosciences will be at Bio Connections Australia.

Pullman Melbourne Albert Park, 19 - 20 Aug 2019

AUM Biosciences will be a part of Bio Connections Australia, an annual national event designed to foster the growth of early phase clinical research in Australia on the 19th and 20th of August, 2019.

Vishal Doshi, Founder and CEO, AUM Biosciences, will speak about “Asia to Global Strategy for Success” as a keynote speaker at the event.

The event brings together a mix of industry executives, researchers and academics. International pharmaceutical and biotechnology companies looking to conduct clinical trial activity in Australia will be a part of the event too.

For visit -

For updates about the event – Stay connected with us on LinkedIn

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.

Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit